Tranexamic Acid

Introduction Overview

Generic Name

tranexamic acid

Brand Name

Cyklokapron

Dosage Form

intravenous solution (10 mg/mL-NaCl 0.7%; 100 mg/mL)

Drug Class

Miscellaneous coagulation modifiers

Pharmacokinetics

Absorption:
Tranexamic acid exhibits good oral bioavailability, approximately 30-50% when administered orally, due to its stable absorption through the gastrointestinal mucosa. Following intravenous administration, absorption is immediate, as the drug directly enters systemic circulation. Its absorption is not significantly affected by food intake, facilitating flexible dosing schedules. Clinical studies demonstrate rapid attainment of peak plasma concentrations after oral administration, typically within 2 to 3 hours. However, intravenous administration results in immediate peak plasma levels, suitable for acute bleeding episodes where rapid hemostasis is critical.

Distribution:
Once absorbed, tranexamic acid distributes extensively into bodily tissues and fluids, including plasma, synovial fluid, and cerebrospinal fluid, reflecting its capacity to reach target sites of fibrinolytic activity. The volume of distribution ranges between 9-12 liters, roughly correlating with extracellular fluid volume. It crosses the placental barrier and is found in breast milk in small amounts, necessitating caution in pregnant and lactating women. Approximately 3% of the drug in plasma is bound to plasma proteins, indicating a predominantly free form that is pharmacologically active. Tissue penetration is clinically relevant in controlling bleeding within diverse anatomical locations.

Metabolism:
Tranexamic acid undergoes minimal hepatic metabolism, which confers an advantage by reducing variability in plasma levels among patients with differing liver function. The drug is largely excreted unchanged by the kidneys. Due to this, hepatic impairment has limited effect on its pharmacokinetics, whereas renal function critically influences elimination and dosing adjustments. The negligible metabolism pathway reduces the risk of pharmacokinetic drug-drug interactions related to hepatic enzyme induction or inhibition.

Elimination:
The principal route of elimination is renal, with approximately 95% of the administered dose excreted unchanged in urine within 24 hours. The elimination half-life ranges from 2 to 3 hours in individuals with normal renal function. In patients with renal impairment, elimination is prolonged, necessitating dose modification to prevent accumulation and potential toxicity. Hemodialysis can effectively remove tranexamic acid from circulation. Due to its renal clearance, careful monitoring is advised in patients with compromised kidney function to avoid adverse events, particularly thrombotic complications.

Dosage Forms

Available Dosage Forms:
- Intravenous solution: 10 mg/mL in 0.7% NaCl; concentrated solution 100 mg/mL.
- Oral tablets (noted in clinical dosing contexts but specific tablet strengths referenced are 650 mg per tablet, commonly administered as two tablets for a 1300 mg dose).

Dosages for Adults and Adolescents:
- For bleeding prevention in hemophilia patients undergoing dental extraction (intravenous): Initial dose of 10 mg/kg given immediately before procedure; maintenance dose 10 mg/kg intravenously three to four times daily for 2 to 8 days. Infusion rate to not exceed 1 mL/min to prevent hypotension.
- For treatment of cyclic heavy menstrual bleeding (oral): 1300 mg (two 650 mg tablets) taken orally three times daily for up to 5 days during menstruation, totaling 3900 mg per day.

Specific Patient Populations:
- Pediatric patients: Dosing mirrors adult recommendations for bleeding prophylaxis during dental procedures; 10 mg/kg intravenously initially, then 10 mg/kg three to four times daily for 2 to 8 days. Oral dosing for menstrual disorders in post-menarchal females similarly matches adults.
- Patients with renal impairment require dose adjustments, though specific regimens depend on severity and are guided clinically; monitoring for potential accumulation is critical.
- The intravenous preparation is specifically utilized in hospital or clinical settings, while oral tablets facilitate outpatient treatment for menstrual bleeding.

Mechanism Of Action

Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its therapeutic effect by competitively inhibiting the activation of plasminogen to plasmin. Plasmin is a serine protease responsible for fibrin clot degradation during fibrinolysis. By binding reversibly to lysine receptor sites on plasminogen molecules, tranexamic acid prevents plasminogen from adhering to fibrin surfaces, thereby stabilizing existing blood clots and reducing excessive hemorrhage.

At the cellular level, the inhibition of plasmin formation preserves the structural integrity of fibrin matrices, which are critical for effective hemostasis. This antifibrinolytic action decreases the breakdown of fibrin clots in various bleeding conditions, including trauma, surgical blood loss, and disease states such as hemophilia-mediated bleeding episodes. Tranexamic acid's interaction avoids interference with coagulation upstream pathways, focusing specifically on fibrinolysis.

Biochemically, tranexamic acid exhibits a high affinity for plasminogen's lysine-binding sites, providing a strong and reversible association that competes with endogenous fibrin. The drug does not activate platelet function or coagulation cascades directly but synergistically enhances clot stability by preventing premature clot dissolution. This specificity affords a favorable safety profile compared to pro-coagulant agents.

Clinical implications of this mechanism include effective reduction in bleeding duration and volume in surgical, dental, and gynecological settings, as well as decreased transfusion requirements. Compared to other antifibrinolytics, such as epsilon-aminocaproic acid, tranexamic acid is more potent and longer acting, allowing for less frequent dosing, a benefit confirmed by multiple clinical studies highlighting reductions in hemorrhage complications and improved patient outcomes.

Pharmacological Actions

Competitive inhibition of plasminogen activation, reducing plasmin formation.
Antifibrinolytic effect stabilizing fibrin blood clots and preventing premature breakdown.
Reduction of bleeding in hemorrhagic conditions by preserving clot integrity.
Facilitation of hemostasis during surgical procedures, trauma, and dental extractions in hemophilic patients.
No direct effect on coagulation factors or platelet aggregation, minimizing thrombotic risk when used appropriately.
Minimal hepatic metabolism leading to predictable pharmacokinetics, especially in liver dysfunction.
Rapid onset of action via intravenous administration enabling acute hemorrhage management.
Oral bioavailability allowing convenient outpatient treatment of heavy menstrual bleeding.
Renal elimination necessitating dose adjustment in renal impairment to avoid accumulation.
Synergistic effect when used alongside factor replacement therapies in hemophilia.
Reversible binding to plasminogen enabling controlled antifibrinolytic activity.
Reduction in blood transfusion requirements in various bleeding scenarios documented in clinical trials.
Effectiveness in both pediatric and adult populations with similar pharmacodynamic profiles.

Therapeutic Or Clinical Uses

Prevention and treatment of bleeding in patients with hemophilia undergoing dental extraction.
Management of acute hemorrhagic episodes to reduce bleeding severity and duration.
Treatment of cyclic heavy menstrual bleeding (menorrhagia) in post-menarchal females.
Adjunctive therapy to reduce the necessity for factor replacement therapy in bleeding disorders.
Use in surgical and trauma settings to control perioperative and post-traumatic bleeding.
Reduction of blood loss during orthopedic surgeries and other major procedures.
Potential use in hereditary angioedema as an antifibrinolytic to control edema.
Management of bleeding associated with thrombocytopenia or platelet function disorders.
Investigational applications in gastrointestinal bleeding control.
Off-label use in epistaxis and other mucosal bleeding conditions.
Prevention of hemorrhage recurrence in patients with recurrent bleeding episodes.
Treatment in conditions with hyperfibrinolysis such as liver cirrhosis-related bleeding.
Use in obstetrics to reduce postpartum hemorrhage under certain clinical protocols.
Reduction of bleeding in patients with factor IX deficiency (hemophilia B).

Side Or Adverse Effects

Nausea, vomiting, and diarrhea as common gastrointestinal symptoms.
Dizziness and light-headedness reported, necessitating caution with driving or hazardous activities.
Mild itching or rash indicating possible hypersensitivity reactions.
Feeling unusually happy or mood elevation noted in some cases.
Risk of serious allergic reactions, including hives, swelling, and difficulty breathing requiring emergency intervention.
Visual disturbances, including changes in color vision, that may necessitate ophthalmologic monitoring.
Potential for seizures, particularly in patients with predisposing factors.
Symptoms indicative of thromboembolic events such as stroke (numbness, weakness, headache), deep vein thrombosis (swelling, warmth), or pulmonary embolism (chest pain, coughing blood).
Blood in urine and painful or difficult urination suggesting urinary tract effects.
Hypotension particularly with intravenous administration if infused too rapidly.
Rare reports of anaphylaxis and severe hypersensitivity reactions.
Confusion and neurological symptoms related to overdose or toxicity.
Potential for blood clot formation warranting monitoring in high-risk patients.
Headache and balance problems as part of central nervous system adverse effects.
Transient vision problems requiring vigilance especially in patients with pre-existing eye vascular disease.

Precautions

Avoid use in patients with known hypersensitivity to tranexamic acid or any formulation components.
Patients with history of thromboembolic disease (stroke, deep vein thrombosis, pulmonary embolism) require careful risk-benefit assessment prior to administration.
Use cautiously in patients with renal impairment with dose adjustments as needed.
Avoid intravenous infusion rates exceeding 1 mL/minute to prevent hypotension.
Monitor vision regularly in patients receiving prolonged therapy or intravenous administration due to risk of ocular vascular events.
Use contraindicated in patients with active intravascular clotting or disseminated intravascular coagulation.
Use with caution in patients with bladder, kidney infections, or history of hematuria.
Pregnancy and breastfeeding status should be disclosed to healthcare providers before initiating treatment.
Patients should be advised against driving or operating heavy machinery until effects on alertness are known.
Inform clinicians regarding use of concomitant anticoagulants or coagulation factor products.
Careful monitoring necessary in patients undergoing surgery to detect excessive thrombosis or bleeding.
Assess risk for color blindness prior to initiating intravenous therapy, as visual side effects may be exacerbated.
Avoid coadministration with drugs increasing thrombosis risk without appropriate monitoring.
Administer under medical supervision with emergency equipment available due to potential allergic reactions.

Warnings

Contraindicated in patients who are color blind, as the drug may exacerbate visual disturbances when given intravenously.
Should not be used in individuals with blood vessel abnormalities in the eyes due to risk of vision damage.
Avoid use in patients with previous history of stroke, blood clot, or bleeding within the brain.
Rapid intravenous administration can cause hypotension; thus, infusion rates must be controlled carefully.
Risk of serious thromboembolic complications including deep vein thrombosis, pulmonary embolism, and stroke.
Discontinue drug immediately if signs of allergic reaction occur, such as swelling, rash, or breathing difficulties.
Use caution in patients with predisposing factors for seizures as tranexamic acid may lower seizure threshold.
Safety during pregnancy has not been fully established, thus it should be used only if clearly needed.
Not advisable in patients with active intravascular clotting, e.g., disseminated intravascular coagulation.
Patients should be informed of potential neurological symptoms such as headaches or dizziness and to seek medical attention if they occur.
Monitoring of blood coagulation status is essential during therapy to detect early thrombotic events.
Use with systemic procoagulants or estrogen-containing medications may increase thrombotic risk.
Withdrawal should be considered if any thrombotic complications emerge during treatment.

Contraindication

Known hypersensitivity or allergy to tranexamic acid or ingredients in the formulation.
History of thromboembolic disease including deep vein thrombosis, pulmonary embolism, or stroke.
Presence of active intravascular clotting, such as disseminated intravascular coagulation (DIC).
Patients with color blindness who are receiving intravenous tranexamic acid.
Patients with vascular abnormalities in the retina or other ocular vascular diseases.
Severe renal impairment without appropriate dose adjustment and monitoring.
Concurrent use with other antifibrinolytic agents or procoagulant therapy that may amplify thrombosis risk.
Pregnant or breastfeeding women unless potential benefits justify potential risks as determined by the healthcare provider.
Patients with history of seizures or epilepsy where the drug may exacerbate condition without caution.
Known active bladder or kidney infections that may worsen with tranexamic acid use.

Drug Interactions

Concomitant use with other antifibrinolytic agents may increase risk of thrombosis.
Interaction with coagulation factor concentrates (e.g., factor IX complex, Bebulin, Profilnine) can potentiate procoagulant effects.
Concurrent administration with systemic estrogen-containing medications may elevate thrombosis risk.
Potential additive effect with anticoagulant and antiplatelet drugs warrants monitoring laboratory coagulation parameters.
Interaction with medications affecting renal elimination may alter tranexamic acid plasma levels.
No significant hepatic enzyme interactions due to minimal hepatic metabolism.
Caution when used with drugs that lower seizure threshold as tranexamic acid may enhance seizure risk.
Over-the-counter medications and herbal supplements that influence blood clotting should be disclosed to healthcare providers.
Potential interactions with medications used in emergency treatment of bleeding require careful clinical judgment.
Drugs affecting renal blood flow or function can alter elimination, necessitating dose adjustments.
Interaction with neuroactive drugs may exacerbate neurological adverse effects such as dizziness or seizures.
Synergistic effect on coagulation when combined with vitamin K antagonists or direct oral anticoagulants has not been fully delineated but requires vigilance.
Concurrent use with NSAIDs may affect renal clearance and bleeding risk profile.
Avoid combining with drugs that promote fibrinolysis as it may reduce tranexamic acid efficacy.

Preparations Of The Drug

Tranexamic acid intravenous solution: 10 mg/mL in 0.7% sodium chloride solution, ready for infusion.
Concentrated intravenous formulation: 100 mg/mL tranexamic acid for dilution prior to administration.
Oral tablet formulations typically supplied as 650 mg per tablet for treatment of heavy menstrual bleeding.
Single-use vials or ampules for intravenous administration to prevent contamination and ensure sterility.
Tablet presentations intended for outpatient use with clear dosing instructions for cyclic heavy menstrual bleeding.
Pharmaceutical-grade sterile injectable preparations maintained at room temperature and protected from light.
Complementary patient information leaflets and instructions for home use following initial clinical administration.
Preparation protocols specify dilutions and infusion rates to avoid adverse events such as hypotension.
Packaging designed for hospital and pharmacy use with barcode and batch tracking for safety.
Availability of branded products such as Cyklokapron and Lysteda reflecting intravenous and oral dosage options respectively.
Regulatory-approved formulations with detailed labeling on indications, contraindications, and administration guidelines.
Manufactured under Good Manufacturing Practice (GMP) conditions ensuring purity, potency, and stability.
Patient counseling materials emphasizing adherence, storage conditions, and disposal of single-use preparations.